Pre- or post-ischemic bilirubin ditaurate treatment reduces oxidative tissue damage and improves cardiac function

Int J Cardiol. 2016 Jan 1:202:27-33. doi: 10.1016/j.ijcard.2015.08.192. Epub 2015 Sep 1.

Abstract

Background: Unconjugated bilirubin (UCB), an endogenous antioxidant, may protect the heart against ischemia-reperfusion (I-R) injury. However, the 'cardioprotective' potential of bilirubin therapy remains unclear. We tested whether pre- or post-ischemic treatment of ex vivo perfused hearts with bilirubin ditaurate (BRT) improves post-ischemic functional outcomes and myocardial oxidative damage.

Methods: Isolated Langendorff perfused hearts (male, Wistar rats) were treated with 50 μM BRT for 30 min before (Pre) or after (Post) 30 min of zero-flow ischemia. Functional outcomes were monitored, with myocardial damage estimated from creatine kinase efflux, infarct size, and left ventricular lipid/protein oxidation assessed by measuring malondialdehyde and protein carbonyls. Ischemia induced contractile dysfunction and cellular injury, with both BRT treatments improving I-R outcomes.

Results: Final post-ischemic recoveries for left ventricular diastolic/developed pressures were significantly enhanced in treated groups: end-diastolic pressure (Control, 78±14, Pre, 51±15*, Post, 51±13 mm Hg*); left ventricular developed pressure, (LVDP; Control 44±15, Pre, 71±19*, Post, 84±13 mm Hg*). Myocardial injury/infarction (MI) was also significantly reduced with BRT treatment: post-ischemic creatine kinase efflux (Control, 1.24±0.41, Pre, 0.86±0.31*, Post, 0.51±0.29 U/g/mL*; infarct size, Control, 67±17, Pre, 39±15*, Post, 22±11%*). These changes were accompanied by significantly reduced malondialdehyde and protein carbonyl content in Pre and Post treated hearts (*P<0.05 vs. Control).

Conclusions: These data collectively reveal significant cardioprotection upon BRT treatment, with post-treatment being particularly effective. Significant reductions in infarct size and lipid and protein oxidation indicate a mechanism related to protection from oxidative damage and indicate the potential utility of this molecule as a post-MI treatment.

Keywords: Antioxidant; Gilbert's syndrome; Heme oxygenase; Myocardial ischemia–reperfusion; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bilirubin / administration & dosage
  • Bilirubin / analogs & derivatives*
  • Coronary Circulation
  • Creatine Kinase / metabolism
  • Disease Models, Animal
  • Gilbert Disease / etiology
  • Gilbert Disease / metabolism
  • Gilbert Disease / prevention & control*
  • Heart Atria / metabolism
  • Heart Atria / pathology
  • Heart Atria / physiopathology
  • Heart Rate / drug effects
  • Heart Rate / physiology
  • Heart Ventricles / drug effects*
  • Heart Ventricles / physiopathology
  • Male
  • Myocardial Reperfusion Injury / complications
  • Myocardial Reperfusion Injury / drug therapy*
  • Myocardial Reperfusion Injury / physiopathology
  • Myocardium / metabolism*
  • Myocardium / pathology
  • Oxidative Stress / drug effects*
  • Rats, Wistar
  • Taurine / administration & dosage
  • Taurine / analogs & derivatives*
  • Treatment Outcome
  • Ventricular Function, Left / drug effects*
  • Ventricular Function, Left / physiology

Substances

  • Taurine
  • bilirubin ditaurine
  • Creatine Kinase
  • Bilirubin